Back to Pipeline

Repotrectinib (ROS1, TRK)


Repotrectinib is an investigational next-generation TKI designed to effectively target ROS1 and TRK A/B/C with potential to treat TKI-naïve or -pretreated patients. In July 2020, Zai Lab obtained exclusive rights to develop and commercialize repotrectinib in Greater China (mainland China, Hong Kong, Macau and Taiwan) from Turning Point Therapeutics, Inc.